Drug treatment of HIV-related opportunistic infections

被引:60
作者
Klepser, ME
Klepser, TB
机构
[1] Div. of Clin. and Admin. Pharmacy, College of Pharmacy, University of Iowa, Iowa City, IA
[2] Div. of Clin. and Admin. Pharmacy, College of Pharmacy, University of Iowa, Iowa City
关键词
D O I
10.2165/00003495-199753010-00004
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The AIDS epidemic has led to the emergence of several disease entities which in the pre-AIDS era were rare or seemingly innocuous, Experience of treating these diseases varies. In some instances, such as Pneumocystis carinii pneumonia, there is an abundance of published literature to direct our course of action, However, for many of these newly recognised diseases our treatment experience is limited. Furthermore, in many instances, well controlled trials evaluating treatment modalities in the AIDS population are lacking, We have identified 13 disease entities (FI carinii pneumonia, toxoplasmosis, cryptococcosis, histoplasmosis, Mycobacterium tuberculosis, Mycobacterium avium complex, cytomegalovirus, coccidioidomycosis, isosporiasis, candidosis, Kaposi's sarcoma, herpes simplex virus, and varicella tester virus) and have reviewed the current literature with regard to their treatment.
引用
收藏
页码:40 / 73
页数:34
相关论文
共 178 条
[1]   CLINICAL AND MYCOLOGICAL EVALUATION OF FLUCONAZOLE IN THE SECONDARY PROPHYLAXIS OF ESOPHAGEAL CANDIDIASIS IN AIDS PATIENTS - AN OPEN, MULTICENTER STUDY [J].
AGRESTI, MG ;
DEBERNARDIS, F ;
MONDELLO, F ;
BELLOCCO, R ;
CAROSI, GP ;
CAPUTO, RM ;
MILAZZO, F ;
CHIODO, F ;
GIANNINI, V ;
MINOLI, L ;
ORTONA, L ;
PASTORE, G ;
PIAZZA, M ;
SCALISE, G ;
CIRELLI, A ;
CHIESI, A ;
GRECO, D ;
VELLA, S ;
CASSONE, A .
EUROPEAN JOURNAL OF EPIDEMIOLOGY, 1994, 10 (01) :17-22
[2]  
*AM THOR SOC, 1994, AM J RESP CRIT CARE, V149, P1359
[3]  
ANAND R, 1993, OPHTHALMOLOGY, V100, P1032
[4]   GANCICLOVIR ABSOLUTE BIOAVAILABILITY AND STEADY-STATE PHARMACOKINETICS AFTER ORAL-ADMINISTRATION OF 2 3000-MG/D DOSING REGIMENS IN HUMAN IMMUNODEFICIENCY VIRUS-SEROPOSITIVE AND CYTOMEGALOVIRUS-SEROPOSITIVE PATIENTS [J].
ANDERSON, RD ;
GRIFFY, KG ;
JUNG, D ;
DORR, A ;
HULSE, JD ;
SMITH, RB .
CLINICAL THERAPEUTICS, 1995, 17 (03) :425-432
[5]   AN OVERVIEW OF THE FURTHER EVALUATION OF PENCICLOVIR AGAINST HERPES-SIMPLEX VIRUS AND VARICELLA-ZOSTER VIRUS IN CELL-CULTURE HIGHLIGHTING CONTRASTS WITH ACYCLOVIR [J].
BACON, TH ;
SCHINAZI, RF .
ANTIVIRAL CHEMISTRY & CHEMOTHERAPY, 1993, 4 :25-36
[6]   FLUCONAZOLE-RESISTANT CANDIDOSIS IN AN HIV COHORT [J].
BAILY, GG ;
PERRY, FM ;
DENNING, DW ;
MANDAL, BK .
AIDS, 1994, 8 (06) :787-792
[7]  
BALFOUR HH, 1994, J ACQ IMMUN DEF SYND, V7, P254
[8]   TUBERCULOSIS IN PATIENTS WITH HUMAN-IMMUNODEFICIENCY-VIRUS INFECTION [J].
BARNES, PF ;
BLOCH, AB ;
DAVIDSON, PT ;
SNIDER, DE .
NEW ENGLAND JOURNAL OF MEDICINE, 1991, 324 (23) :1644-1650
[10]   CLINICAL EFFECTS AND INVITRO STUDIES OF TRIFLUOROTHYMIDINE COMBINED WITH INTERFERON-ALPHA FOR TREATMENT OF DRUG-RESISTANT AND DRUG-SENSITIVE HERPES-SIMPLEX VIRUS-INFECTIONS [J].
BIRCH, CJ ;
TYSSEN, DP ;
TACHEDJIAN, G ;
DOHERTY, R ;
HAYES, K ;
MIJCH, A ;
LUCAS, CR .
JOURNAL OF INFECTIOUS DISEASES, 1992, 166 (01) :108-112